Navigation Links
Januvia Lawsuits Being Investigated By Bernstein Liebhard LLP on Behalf of Januvia Patients Who Were Diagnosed with Pancreatic Cancer, Pancreatitis and Thyroid Cancer
Date:8/11/2013

New York, New York (PRWEB) August 11, 2013

Bernstein Liebhard LLP is investigating Januvia lawsuits (http://www.thejanuvialawsuit.com/) on behalf of Type 2 diabetics who took Januvia and were later diagnosed with pancreatic cancer, pancreatitis or thyroid cancer. According to court documents, a growing number of Januvia lawsuits have been filed against Merck & Co. that accuse the drug maker of failing to warn doctors and patients of an association between the use of Januvia and pancreatic cancer, as well as pancreatitis. The U.S. Judicial Panel on Multidistrict Litigation (JPML) is expected to make a decision soon regarding the establishment of a multidistrict litigation for all federal lawsuits involving allegations that Januvia and similar diabetes medications can increase risks for pancreatic cancer, pancreatitis and thyroid cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

“We have heard from a number of Januvia users who have been diagnosed with pancreatic cancer, pancreatitis and thyroid cancer. The body of evidence pointing to a possible connection between the use of drugs like Januvia and an increased risk for these diseases continues to grow,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Januvia lawsuit consultations to anyone who may have been harmed after taking Januvia or a similar drug.

Januvia and Pancreatic Cancer
Januvia belongs to a class of type 2 diabetes drugs known as incretin mimetics, which help regulate blood sugar by stimulating insulin production by the pancreas. In 2009, a caution regarding a potential Januvia pancreatitis risk was added to the drug’s label after the U.S. Food & Drug Administration (FDA) became aware of 88 post-marketing cases of acute pancreatitis in patients taking Januvia.* In 2011, a study published in Gastroenterology found that use of Januvia appeared to increase the risk of pancreatitis and pancreatic cancer, while two cases of thyroid cancer were also reported in the patients who took Januvia.**

The FDA announced in March that it was investigating incretin mimetics after results from an unpublished study indicated these medications might cause pre-cancerous changes in the pancreas. While the agency has not yet been able to confirm a conclusive link between the use of such drugs and pancreatic cancer, it has said its “review is ongoing as pancreatitis and pancreatic cancer data are being collected.”*** Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.****

Patients who have developed pancreatic cancer, thyroid cancer or pancreatitis that may be related to the use of Januvia could be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn More about the possible link between Januvia and pancreatic cancer by visiting Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/ucm343187.htm
**http://www.gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
***pharmalive.com/fda-decides-no-risk-of-pancreatic-cancer-with-diabetes-drugs, Pharmalot, July 31, 2013
****bmj.com/open-data/incretin#alternate; BMJ, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thejanuvialawsuit.com/

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb11015829.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Januvia Pancreatic Cancer Lawsuit: Bernstein Liebhard LLP Comments on Growing Litigation Surrounding Januvia
2. Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
3. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
4. New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
5. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
6. Januvia Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Medical Journal’s Investigation of Incretin Mimetics
7. Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
8. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
9. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
10. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
11. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... ... 2017 , ... In its ongoing effort to educate consumers ... and published an informational resource that addresses frequently asked questions. , “ ... site’s team of third party administrator (TPA) contributors regularly receives as employers, benefit ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... a common and unwelcomed occurrence in people of all ages, genders and ethnicities. Dermatologist Dr. ... of dealing with excess skin oil. “Oily skin is a challenge to many of my ... the oily shine while keeping the skin fresh and clean,” says Dr. Au. , What ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), a ... serious pulmonary diseases, today announced that it has added two ... and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the Pediatric ... Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 ... to reach USD 16.0 billion by 2025, according to ... growing prevalence of chronic diseases is anticipated to be ... analyzers, which thereby widens the scope for growth during ... and bariatric population, which is highly susceptible to chronic ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
Breaking Medicine Technology: